DOCSLIB.ORG

USP Endotoxin Limits for Common Injectables

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USP Endotoxin Limits for Common Injectables Pharma&Biotech USP Endotoxin Limits for Common Injectables Updated as of August 2011 For reference use only Pharma&Biotech Updated as of August 2011. For reference use only. USP Endotoxin Limits This information is subject to the disclaimer included on page 13. for Common Injectables This table is for informational purposes only. Endotoxin limits should be set on an individual product basis, using the formula found in the Pharmacopeias (Endotoxin Limit = K/M). Description Endotoxin Limit A Acepromazine Maleate Injection 4.5 EU / mg Acetazolamide for Injection 0.5 EU / mg Acetic Acid Irrigation 0.5 EU / ml Acyclovir for Injection 0.174 EU / mg Adenosine Injection (continuous peripheral intravenous infusion) 5.95 EU / mg Adenosine Injection (rapid intravenous) 11.62 EU / mg Alcohol in Dextrose Injection 0.5 EU / ml Alfentanil Injection 10 EU / ml Alprostadil Injection 0.05 EU / µg Alteplase for Injection 1 EU / mg Amifostine for Injection 0.2 EU / mg Amikacin Sulfate Injection 0.33 EU / mg Aminocaproic Acid Injection 0.05 EU / mg Aminohippurate Sodium Injection 0.04 EU / mg Aminopentamide Sulfate Injection 25 EU / mg Aminophylline Injection 1 EU / mg Ammonium Chloride Injection (of Chloride) 1.72 mEq Cl Amobarbital Sodium for Injection 0.4 EU / mg Amoxicillin, Sterile and Suspension 0.25 EU / mg Amphotericin B for Injection (for Intrathecal) 0.9 EU / mg Amphotericin B for Injection (for Parenterals) 5 EU / mg Ampicillin and Sulbactam for Injection 0.17 EU / (1 mg of mix of amp and sulb - 0.67 and 0.33 mg, respectively) Ampicillin for Injection 0.15 EU / mg Anileridine 7.2 EU / mg Aprotinin Injection 0.14 unit Arginine Hydrochloride Injection 0.01 EU / mg Ascorbic Acid Injection 1.2 EU / mg Atenolol Injection 33.3 EU / mg Atracurium Besylate Injection 5.56 EU / mg Atropine Sulfate 55.6 EU / mg of azathioprine Aurothioglucose Suspension 7.14 EU / mg Azathioprine Sodium for Injection 1 EU / mg Azithromycin for Injection 0.7 EU / mg Aztreonam for Injection 0.17 EU / mg if labeled sterile or processed into injectable B Bacitracin for Injection 0.01 EU / Bacitracin unit if labeled sterile or processed into injectable Bacteriostatic Sodium Chloride Injection 1 EU / ml Bacteriostatic Water for Injection (WFI), Sterile 0.5 EU / ml Benztropine Mesylate Injection 55.6 EU / mg Benzylpenicilloyl Polylysine Injection 5833 EU / ml Betamethasone Acetateand Betametthasone Sodium Phosphate injectable 29.2 EU / mg Suspension Betamethasone Sodium Phosphate 29.2 EU / mg Betamethasone Customer Service: US 800 638 8174, EU + 32 87 321 611 ; Scientific Support: US 800 521 0390, EU +32 87 321 611 2 Updated as of August 2011. For reference use only. This information is subject to the disclaimer included on page 13. Description Endotoxin Limit Bethanechol Chloride Injection 25 EU / mg Biperiden Lactate Injection 83.3 EU / mg Bleomycin for Injection 10 EU / Bleomycin Unit Bretylium Tosylate in Dextrose Injection 0.2 EU / mg Bretylium Tosylate Bretylium Tosylate Injection 0.2 EU / mg Brompheniramine Maleate Injection 35.7 EU / mg Bumetanide Injection 350 EU / mg Bupivacaine Hydrochloride and Epinephrine Injection 1.6 EU / mg Bupivacine Hydrochloride Bupivacaine Hydrochloride and Dextrose 1.8 EU / mg Bupivacine Hydrochloride Bupivacaine Hydrochloride Injection 2.5 EU / mg Butorphanol Tartrate Injection 88 EU / mg C Caffeine and Sodium Benzoate Injection 0.7 EU / mg Caffeine Citrated 0.25 EU / mg Calcitonin - Salmon 0.625 unit Calcitriol Injection 100 EU / µg Calcium Chloride 0.2 EU / mg Calcium Gluceptate Injection 0.32 EU / mg Calcium Gluconate 0.17 EU / mg Calcium Levulinate Injection 35.7 EU / mg Capreomycin for Injection 0.35 EU / mg Carbenicillin for Injection 0.05 EU / mg Carboplatin for Injection 0.54 EU / mg Carboprost Tromethamine 714.3 EU / mg Carmustine for Injection 0.95 EU / mg Cefamandole Nafate for Injection 0.15 EU / mg Cefamandole Cefazolin Injection 0.15 EU / mg Cefepime for Injection 0.06 EU / mg Cefepime Hydrochloride 0.04 EU / mg if labeled sterile or processed into injectable Cefmetazole for Injection 0.2 EU / mg Cefonicid for Injection 0.35 EU / mg Cefoperazone Injection 0.2 EU / mg Ceforanide 0.25 EU / mg if labeled sterile or processed into injectable Cefotaxime Sodium for Injection 0.2 EU / mg Cefotetan for Injection 0.17 EU / mg if labeled sterile or processed into injectable Cefoxitin for Injection 0.13 EU / mg Ceftazidime 0.1 EU / mg if labeled sterile or processed into injectable Ceftizoxime for Injection 0.1 EU / mg Ceftriaxone Injection 0.2 EU / mg Cefuroxime for Injection 0.1 EU / mg Cephalothin for Injection 0.13 EU / mg Cephapirin for Injection 0.17 EU / mg Cephradine for Injection 0.2 EU / mg Chloramphenicol Sodium Succinate 0.2 EU / mg of Chloramphenicol if labeled sterile or processed into injectable Chlordiazepoxide Hydrochloride 3.57 EU / mg Chloroquine Hydrochloride Injection 0.7 EU / mg Chlorothiazide Sodium 0.3 EU / mg Chlorpheniramine Maleate 8.8 EU / mg Chlorpromazine Hydrochloride 6.9 EU / mg Chorionic Gonadotropin 0.03 EU / USP Chorionic Gonadotropin Unit Customer Service: US 800 638 8174, EU + 32 87 321 611 ; Scientific Support: US 800 521 0390, EU +32 87 321 611 3 Pharma&Biotech Updated as of August 2011. For reference use only. USP Endotoxin Limits This information is subject to the disclaimer included on page 13. for Common Injectables Description Endotoxin Limit Chromate Sodium Cr5l Injection 175 / V EU / ml (V = max. total dose in ml at the expiration time) Chromic Chloride Injection 16.7 EU / µg of chromium Chromic Phosphate P32 Suspension 175 / V EU / ml (V = max. total dose in ml at the expiration time) Chromium Cr 51 Edetate Injection 175 / V EU / ml (V = max. total dose in ml at the expiration time) Cilastatin Sodium 0.17 EU / mg of cilastatin if labeled sterile Cimetidine Injection 0.5 EU / mg Ciprofloxacin for Injection 0.5 EU / mg Cisplatin for Injection 2 EU / mg Citric Acid, Magnesium Oxide and Sodium Carbinate Irrigation 2.8 EU / ml Clavulanate Potassium 0.03 EU / mg if labeled sterile or processed into injectable Clindamycin for Injection 0.58 EU / mg Cloprostenol Injection 2500 EU / mg Codeine Phosphate Injection 5.8 EU / mg Colchicine Injection 166.7 EU / mg Colistimethate for Injection 2 EU / mg if labeled sterile or processed into injectable Corticotropin Injection 3.1 EU / USP Corticotropin Unit Cupric Chloride Injection 250 EU / mg of copper Cupric Sulfate Injection 250 EU / mg of copper Cyanocobalamine Injection 0.4 EU / µg Cyclophosphamide for Injection 0.2 EU / mg Cyclosporine Injection 0.84 EU / mg (use 1:10 dilution; mix 0.1 ml with 0.1 ml LAL reagent on vortex mixer for 5 seconds) Cysteine Hydrochloride for Injection 0.7 EU / mg Cytarabine for Injection 0.07 EU / mg if labeled sterile or processed into injectable D Dacarbazine for Injection 0.52 EU / mg Dactinomycin for Injection 100 EU / mg Dantrolene Sodium 0.5 EU / mg Daunorubicin Hydrochloride for Injection 4.3 EU / mg of Daunorubicin Deferoxamine Mesylate for Injection 0.33 EU / mg if labeled sterile or processed into injectable Desmopressin Acetate 10 EU / µg Desoxycorticosterone Acetate 71.4 EU / mg Desoxycorticosterone Pivalate Suspension 2.78 EU / mg Dexamethasone Acetate Injectable Suspension 21.7 EU / mg Dexamethasone Injection 21 EU / mg Dexamethasone Sodium Phosphate Injection 31.3 EU / mg Dextran 1 25 EU / g Dextran 40 in Dextrose Injection 1 EU / ml Dextran 40 in Sodium Chloride Injection 1 EU / ml Dextran 70 in Dextrose Injection 0.5 EU / ml Dextran 70 in Sodium Chloride Injection 0.5 EU / ml Dextrose (<5%) Injection 0.5 EU / ml for injections containing less than 5% of Dextrose Dextrose (5-70%) Injection 10 EU / g for injections containing less than 5% and 70% of Dextrose Dextrose and Sodium Chloride Injection 10 EU / g Diatrizoate Meglumine and Diatrizoate Sodium 34.3%-35% 1.8 EU / ml Diatrizoate Meglumine and Diatrizoate Sodium 28.5%-29.1% 1.8 EU / ml Diatrizoate Meglumine and Diatrizoate Sodium 50%-25% 1.8 EU / ml Diatrizoate Meglumine and Diatrizoate Sodium 52%-8% 1.8 EU / ml Diatrizoate Meglumine and Diatrizoate Sodium 60%-30% 3.6 EU / ml Diatrizoate Meglumine and Diatrizoate Sodium 66%-10% 3.6 EU / ml Diatrizoate Meglumine Injection <50% 1.1 EU / ml for injections containing less than 50% Diatrizoate Meglumine Customer Service: US 800 638 8174, EU + 32 87 321 611 ; Scientific Support: US 800 521 0390, EU +32 87 321 611 4 Updated as of August 2011. For reference use only. This information is subject to the disclaimer included on page 13. Description Endotoxin Limit Diatrizoate Meglumine Injection > or equal to 50% 5 EU / ml for injections containing less than 50% Diatrizoate Meglumine Diatrizoate Sodium 20% 5.6 EU / ml for injections containing 20% of Diatrizoate Sodium Diatrizoate Sodium 25% 1.3 EU / ml for injections containing 25% of Diatrizoate Sodium Diatrizoate Sodium 50% 5 EU / ml for injections containing 50% of Diatrizoate Sodium Diazepam Injection 11.6 EU / mg Diazoxide Injection 0.5 EU / mg Dibucaine Hydrochloride Injection 35.7 EU / mg Dicyclomine Hydrochloridel Injection 17.2 EU / mg Diethylstilbestrol Injection 0.7 EU / mg Digitoxin Injection 111 EU / mg Digoxin Injection 200 EU / mg Dihydroergotamine Mesylate Injection 175 EU / mg Dihydrostreptomycin Injection 0.5 EU / mg Dimercaprol 1 EU / mg Dimethyl Sulfoxide Irrigation 0.5 EU / ml Dinoprost Tromethamine 8 EU / mg Diphenhydramine Hydrochloride Injection 3.4 EU / mg Dipyridamole Injection 8.8 EU / mg Dobutamine for Injection 5.56 EU / mg Dobutamine in Dextrose Injection 5.56 EU / mg Doputamine Docetaxel 0.3 EU / mg Dolasetron Mesylate
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • Use of Chemical Chelators As Reversal Agents for Drug
    (19) TZZ_ _ZZZ_T (11) EP 1 210 090 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/724 (2006.01) A61K 31/194 (2006.01) 18.06.2014 Bulletin 2014/25 A61P 39/04 (2006.01) (21) Application number: 00964006.1 (86) International application number: PCT/EP2000/007694 (22) Date of filing: 07.08.2000 (87) International publication number: WO 2001/012202 (22.02.2001 Gazette 2001/08) (54) USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCK VERWENDUNG VON CHEMISCHEN CHELATOREN ZUR UMKEHRUNG VON PHARMAKOLOGISCH-INDUZIERTER NEUROMUSKULÄRER BLOCKIERUNG UTILISATION D’AGENTS CHIMIQUES CHELATANTS COMME AGENTS DE NEUTRALISATION DU BLOCAGE NEUROMUSCULAIRE PROVOQUE PAR DES MEDICAMENTS (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU AU-A- 3 662 895 MC NL PT SE • B DESIRE: "Inactivaton of sarin and soman by (30) Priority: 13.08.1999 EP 99306411 cyclodextrins in vitro" EXPERIENTIA, vol. 43, no. 4, 1987, pages 395-397, XP000907287 (43) Date of publication of application: • B. DESIRE: "Interaction of soman with beta- 05.06.2002 Bulletin 2002/23 cyclodextrin" FUNDAMENTAL AND APPLIED TOXICOLOGY, vol. 7, no. 4, 1986, pages 647-657, (73) Proprietor: Merck Sharp & Dohme B.V. XP000911170 2031 BN Haarlem (NL) • C. MAY: "Development of a toxin-binding agent as a treatment for tunicamycinuracil toxicity: (72) Inventors: protection against tunicamycin poisoning of • BOM, Antonius, Helena, Adolf sheep" AUSTRALIAN VETERINARY JOURNAL, Ratho, Midlothian EH28 8NY (GB) vol. 76, no.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Expression of Multiple Populations of Nicotinic Acetylcholine
    EXPRESSION OF MULTIPLE POPULATIONS OF NICOTINIC ACETYLCHOLINE RECEPTORS IN BOVINE ADRENAL CHROMAFFIN CELLS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Bryan W. Wenger, B.A. The Ohio State University 2003 Dissertation Committee: Approved by: Professor Dennis B. McKay, Advisor Professor R. Thomas Boyd ________________________ Advisor Professor Popat N. Patil College of Pharmacy Professor Lane Wallace, Ph.D. ABSTRACT The importance of the role of nAChRs in physiological and pathological states is becoming increasingly clear. It is apparent that there are multitudes of nAChR subtypes with different expression patterns, pharmacologies and functions that may be important in various disease states. Therefore, a greater understanding of nAChR subtypes is essential for potential pharmacological intervention in nAChR systems. Bovine adrenal chromaffin cells are a primary culture of a neuronal type cell that express ganglionic types of nAChRs whose activation can be related to a functional response. While much is known about the outcome of functional activation of adrenal nAChRs, little work has been done in characterizing populations of nAChRs in adrenal chromaffin cells. These studies characterize the pharmacology and regulation of populations of nAChRs found in bovine adrenal chromaffin cells. The primary findings of this research include 1) the characterization of an irreversible antagonist of adrenal nAChRs, 2) the discovery of
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Kinevac® (Sincalide) For Injection 5 mcg/vial Diagnostic Cholecystokinetic Bracco Imaging Canada Date of Initial Approval: Montreal, Quebec July 2, 1996 Canada, H1J 2Z4 Date of Revision: October 30, 2019 Submission Control No: 231066 Product Monograph Kinevac® Page 1 of 14 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 1 INDICATIONS ................................................................................................................. 3 Pediatrics ........................................................................................................................ 3 Geriatrics ......................................................................................................................... 3 2 CONTRAINDICATIONS .................................................................................................. 3 3 DOSAGE AND ADMINISTRATION ................................................................................ 4 Recommended Dose and Dosage Adjustment ................................................................ 4 Reconstitution .................................................................................................................. 4 4 OVERDOSAGE ..............................................................................................................
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born Et A1
    US007265099B1 (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born et a1. (45) Date of Patent: *Sep. 4, 2007 (54) USE OF CHEMICAL CHELATORS AS Tarver, G. et al “2-O-Substituted cyclodextrins as reversal REVERSAL AGENTS FOR DRUG-INDUCED agents . ” Bioorg. Med. Chem. (2002) vol. 10, pp 1819-1827.* NEUROMUSCULAR BLOCK Zhang, M. “Drug-speci?c cyclodextrins . ” Drugs of the Future (2003) vol. 28, no 4, pp 347-354.* (75) Inventors: Antonius Helena Adolf Bom, Lee, C. “Structure, conformation, and action of neuromuscular Midlothian (GB); Alan William Muir, blocking drugs” Brit. J. Anesth. (2001) vol. 87, no 5, pp 755-769.* Lanark (GB); David Rees, Gothenburg B Desire: “Inactivation of sarin and soman by cyclodextrins in (SE) vitro” EXPERIENTIA, vol. 43, No. 4, 1987, pp. 395-397. B. Desire: “Interaction of soman with beta-cyclodextrin” Funda (73) Assignee: Organon N.V., Oss (NL) mental and Applied Toxicology, vol. 7, No. 4, 1986, pp. 647-657. ( * ) Notice: Subject to any disclaimer, the term of this C. May: “Development of a toxin-bindng agent as a treatment for patent is extended or adjusted under 35 tunicamycinuracil toxicity: protection against tunicamycin poison U.S.C. 154(b) by 0 days. ing of sheep” Australian Veterinary Journal, vol. 76, No. 11, 1998 pp. 752-756. This patent is subject to a terminal dis K. Uekama: “Effects of cyclodextrins on chlorpromaZine-induced claimer. haemolysis and nervous systems responses” J. Pharm. Pharmacol., vol. 33, No. 11, 1981, pp. 707-710. (21) Appl. No.: 10/049,393 T. Irie: “Protective mechanism of beta-cyclodextrin for the hemolysis induced With phenothiazine neuroleptics in vitro” J.
    [Show full text]
  • Chapter 12 Monographs of 99Mtc Pharmaceuticals 12
    Chapter 12 Monographs of 99mTc Pharmaceuticals 12 12.1 99mTc-Pertechnetate I. Zolle and P.O. Bremer Chemical name Chemical structure Sodium pertechnetate Sodium pertechnetate 99mTc injection (fission) (Ph. Eur.) Technetium Tc 99m pertechnetate injection (USP) 99m ± Pertechnetate anion ( TcO4) 99mTc(VII)-Na-pertechnetate Physical characteristics Commercial products Ec=140.5 keV (IT) 99Mo/99mTc generator: T1/2 =6.02 h GE Healthcare Bristol-Myers Squibb Mallinckrodt/Tyco Preparation Sodium pertechnetate 99mTc is eluted from an approved 99Mo/99mTc generator with ster- ile, isotonic saline. Generator systems differ; therefore, elution should be performed ac- cording to the manual provided by the manufacturer. Aseptic conditions have to be maintained throughout the operation, keeping the elution needle sterile. The total eluted activity and volume are recorded at the time of elution. The resulting 99mTc ac- tivity concentration depends on the elution volume. Sodium pertechnetate 99mTc is a clear, colorless solution for intravenous injection. The pH value is 4.0±8.0 (Ph. Eur.). Description of Eluate 99mTc eluate is described in the European Pharmacopeia in two specific monographs de- pending on the method of preparation of the parent radionuclide 99Mo, which is generally isolated from fission products (Monograph 124) (Council of Europe 2005a), or produced by neutron activation of metallic 98Mo-oxide (Monograph 283) (Council of Europe 2005b). Sodium pertechnetate 99mTc injection solution satisfies the general requirements of parenteral preparations stated in the European Pharmacopeia (Council of Europe 2004). The specific activity of 99mTc-pertechnetate is not stated in the Pharmacopeia; however, it is recommended that the eluate is obtained from a generator that is eluted regularly, 174 12.1 99mTc-Pertechnetate every 24 h.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe Et Al
    USOO6803046B2 (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe et al. (45) Date of Patent: Oct. 12, 2004 (54) SINCALIDE FORMULATIONS OTHER PUBLICATIONS (75) Inventors: Edmund C. Metcalfe, Hillsborough, NJ Sitzmann, et al., “Cholecystokinin Prevents Parenteral (US); Jo Anna Monteferrante, Raritan Nutrition Induced Biliary Sludge in Humans.” Surgery, Township, NJ (US); Margaret Gynecology & Obstetrics, vol. 170, Jan. 1990, pp. 25-31. Newborn, Hamilton Township, NJ Teitelbaum et al., “Treatment of Parenteral Nutrition-ASSo (US); Irene Ropiak, Lawrenceville, NJ ciated Cholestasis with Cholecystokinin-Octapeptide,” (US); Ernst Schramm, North Journal of Pediatric Surgery, vol. 30, No. 7, Jul. 1995, pp. Brunswick, NJ (US); Gregory W. 1082-1085. White, Monmouth Junction, NJ (US); Moss and Amii, “New Approaches to Understanding the Julius P. Zodda, Mercerville, NJ (US) Etiology and Treatment of Total Parenteral Nutrition-ASSo ciated Cholestasis,” Seminars in Pediatric Surgery, vol. 8, (73) Assignee: Bracco International B.V., Amsterdam No. 3, Aug. 1999, pp. 140–147. (NL) Teitelbaum, "Parenteral Nutrition-ASSociated Cholestasis,” c: - Current Opinion in Pediatrics, vol. 9, 1997, pp. 270–275. (*) Notice: Subject to any State the SME, tly Teitelbaum and Tracy, “Parenteral Nutrition-Associated patent is extended or adjusted under Cholestasis,” Seminars in Pediatric Surgery, vol. 10, No. 2, U.S.C. 154(b) by 0 days. May 2001, pp. 72–80. Strickley, “Parenteral Formulations of Small Molecules (21) Appl. No.: 10/222,540 Therapeutics Marketed in the United States (1999) -Part (22) Filed: Aug. 16, 2002 1, PDA Journal of Pharmaceutical Science & Technology, e - Vs vol. 53, No. 6, Nov.-Dec. 1999, pp.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Jan 19, 2009 Listing of Generic, Non
    http://www.medword.com/uspa.html Jan 19, 2009 Listing of generic, non-prescription, prescription, and OTC (over-the-counter) p harmaceuticals A-200 Gel Concentrate A-200 Shampoo Concentrate A-25 A-Cillin A-Fil A-Hydrocort A-methaPred A-Phedrin A-Spas S/L A Plus A.C. & C. A.P.L. A.R.M. Allergy Relief A.R.M. Maximum Strength Caplets A/B Otic A/Fish Oil A/T/S abacavir abarelix-depot-F abarelix-depot-M Abbokinase Abbokinase Open-Cath Abelcet Abenol Abitrate Absorbine Athletes Foot Absorbine Jock Itch Absorbine Jr. Antifungal AC acarbose Accolate Accupep HPF Accupril Accuretic Accutane Accutane Roche acebutolol Acel-Imune Acellular DTP Aceon Acet-2 Acet-3 Acet Codeine 30 Acet Codeine 60 Aceta Aceta Elixir Aceta Tablets acetaminophen acetaminophen-butalbital acetaminophen-caffeine acetaminophen-chlorpheniramine acetaminophen-codeine acetaminophen-dextromethorphan acetaminophen-diphenhydramine acetaminophen-hydrocodone acetaminophen-oxycodone acetaminophen-phenyltoloxamine acetaminophen-propoxyphene acetaminophen-propoxyphene hydrochloride acetaminophen-propoxyphene napsylate acetaminophen-pseudoephedrine acetazolam acetazolamide Acetest acetic acid Acetocot acetohexamide acetophenazine Acetoxyl 10 Gel Acetoxyl 2.5 Gel Acetoxyl 20 Gel Acetoxyl 5 Gel acetylsalicylic acid Achromycin Achromycin V aciclovir Acid Control Acid Phos Fluor Rinse Acilac Aciphex acitretin Aclophen Aclovate Acne-10 Lotion Acne-5 Lotion Acne-Aid Aqua Gel Acne-Aid Gel Acne-Aid Vanishing Cream Acne Aid 10 Cream Acne Lotion 10 Acne Prone Skin Sunscreen Acne Wash Acno Acnomel
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]